Main Article Content
OBJECTIVE: To evaluate anti-hyperglycemic and anti-oxidative effects of L-carnitine in alloxan induced diabetic albino wistar rats.
METHODS: This quasi-experimental study was conducted at Isra University, Hyderabad from June 2017 to August 2017. Thirty-six albino wistar male rats were equally divided into 3 groups (n=12/group); group A (control), group B (alloxan 150mg/kg intraperitoneally) and group C (alloxan 150mg/kg intraperitoneally + L-carnitine 500mg/kg orally for 21 days). Diabetes was induced in group B and C by single intraperitoneal dose of alloxan 150mg/kg body weight and rats having blood glucose >200mg/dl were labeled as diabetic rats and included in study. Biochemical (blood glucose, serum insulin and glutathione peroxidase) and histopathological analysis of pancreas was performed in all three experimental groups.
RESULTS: Post-experimental body weight in groups A, B and C were noted as 249.58±6.63, 199.08±12.18, 210.58±5.14 grams respectively. The fasting blood glucose in groups A, B and C were noted as 104.58±7.05, 221.25±8.22, 110.17±12.85 mg/dl respectively (P<0.001). Serum insulin in groups A, B and C was noted as 1.45±0.083, 0.31±0.16, 1.74±0.23 ηg/ml respectively (P<0.001). Glutathione peroxidase levels in groups A, B and C were noted as 1.45±0.17, 0.93±0.11, 1.74±0.17 ηg/ml respectively (P<0.001). Histopathology of pancreas showed reduction in size (mean islet diameter 157±1.5 µm) and number of islets of Langerhans in diabetic rats, while L-carnitine treated rats have shown compensatory increase in size of islets of Langerhans (mean islet diameter 210±6.3 µm).
CONCLUSION: L-carnitine therapy is a potent anti-hyperglycemic and anti-oxidative regimen capable of reducing blood glucose and increasing plasma anti-oxidant levels.
Work published in KMUJ is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
2. Lenzen S. The mechanisms of alloxan-and streptozotocin-induced diabetes. Diabetologia 2008;51(2):216-26.DOI: 10.1007/s00125-007-0886-7
3. Danilova I, Sarapultsev P, Medvedeva S, Gette I, Bulavintceva T, Sarapultsev A. Morphological restructuring of myocardium during the early phase of experimental diabetes mellitus. Anat Rec (Hoboken) 2015;298(2):396-407. DOI: 10.1002/ar.23052
4. Derosa G, Limas CP, Macías PC, Estrella A, Maffioli P. Dietary and nutraceutical approach to type 2 diabetes. Arch MedSci 2014;10(2):336-42. DOI: 10.5114/aoms.2014.42587
5. Salmanoglu DS, Gurpinar T, Vural K, Ekerbicer N, Darıverenli E, Var A. Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in Type 2 diabetic rats. Redox Biol 2016;8:199-204. DOI: 10.1016/j.redox.2015.11.007
6. Shiblawi WM, Ismael SH. The Effect of L-Carnitine as an Adjuvant Supplement on Lipid Profile in Iraqi Diabetic Patients. Iraqi J Pharm Sci 2015;24(2):48-52.
7. Humadi MHM, Mubarak ZM, Jamil IJ. The Effects of Leptin Hormone Concentrations and Some Immunological and Biochemical Parameters in Alloxan Induced Diabetic Male Rabbits and Diabetic Treated with Alpha Lipoic Acid and L-Carnitine. Tikrit J Pure Sci 2018;22(2):1-7.
8. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007;10(2):142-8. DOI: 10.1097/MCO.0b013e328042ba90
9. An JH, Kim YJ, Kim KJ, Kim SH, Kim NH, Kim HY, et al. L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment: a randomized, double-blind, placebo-controlled trial. Endocr J 2016;63(10):885-95. DOI: 10.1507/endocrj.EJ16-0109
10. Lee BJ, Lin JS, Lin YC, Lin PT. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition 2015;31(3):475-9. DOI: 10.1016/j.nut.2014.10.001
11. Liu L, Zhang D, Wang M, Fan C, Zhou F, Wang S, et al. The adverse effects of long-term l-carnitine supplementation on liver and kidney function in rats. Hum Exp Toxicol 2015;34(11):1148-61. DOI: 10.1177/0960327115571767
12. Giesbertz P, Ecker J, Haag A, Spanier B, Daniel H. An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues. J Lipid Res 2015;56(10):2029-39. DOI: 10.1194/jlr.D061721
13. Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, et al. Impact of L-carnitine on plasma lipoprotein (a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep 2016;6:19188. DOI: 10.1038/srep19188
14. Charan J, Kantharia N. How to calculate sample size in animal studies? J Pharmacol Pharmacother 2013;4(4):303. DOI: 10.4103/0976-500X.119726
15. Mohammed A, Adelaiye A, Bakari A, Mabrouk M. Anti-diabetic and some haematological effects of ethylacetate and n-butanol fractions of Ganoderma lucidum aqueous extract in alloxan-induced diabetic wistar rats. Int J Med Med Sci 2009;1(12):530-5.
16. Cotter M, Cameron N, Keegan A, Dines K. Effects of acetyl-and proprionyl-L-carnitine on peripheral nerve function and vascular supply in experimental diabetes. Metabolism 1995;44(9):1209-14. DOI: 10.1016/0026-0495(95)90018-7
17. Sutradhar A, Sarkar AP, Saleh MA, Mondal M, Wahed TB, Ahmed S, et al. Investigation of antidiabetic and antilipidemic effect of fruit extract of Spondias pinnata (Amra) in alloxan induced hyperglycemic rats. J Pharmacog Phytochem 2018;7(5):2785-9. DOI: 10.13140/RG.2.2.28924.39045
18. Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. Front Physiol 2014;5:352. DOI: 10.3389/fphys.2014.00352
19. Samir SM, Abbas AM, Safwat SM, Elserougy HG. Effect of L-Carnitine on diabetes-induced changes of skeletal muscles in rats. J Basic Clin Physiol Pharmacol 2018;29(1):47-59. DOI: 10.1515/jbcpp-2016-0185
20. Sasaninejad Z, Eidi M, Khanehsar MA, Ghahramani R, Torabi F. Effect of L-Carnitine on Serum Parameters in Alloxan-induced Diabetic male rats. Adv Biores 2015;6(3):120-3. DOI: 10.15515/abr.0976-45184.108.40.206-123
21. Sadighara M, Joktaji JP, Hajhashemi V, Minaiyan M. Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats. Res Pharm Sci 2017;12(6):434-43. DOI: 10.4103/1735-5362.217424
22. Abuzahra MAE-L, Mustafa SA-E. Nitric Oxide and Oxidative Stress Properties of L-Carnitine in Diabetic Hypertensive Rats Biochemical and Histological Study. Middle East J Intern Med 2014;63(1198):1-13. DOI: 10.5742/MEIM.2014.92498
23. Hall JA, Yerramilli M, Obare E, Yerramilli M, Melendez LD, Jewell DE. Relationship between lean body mass and serum renal biomarkers in healthy dogs. J Vet Intern Med 2015;29(3):808-14. DOI: 10.1111/jvim.12607
24. Amiri-Moghadam S, Nematy M, Eghtesadi S, Khalili M, Mojarrad M, Jazayeri S, et al. SUN-P061: Effects of L-Carnitine Supplementation on Body Composition in Patients with Nonalcoholic Steatohepatitis. Clin Nutr 2017;36:S76. DOI: 10.1016/S0261-5614(17)30566-6
25. Nagy M. Antioxidant and antiapoptotic effects of Hydroclathrus clathratus on hepatic dysfunction in alloxan-induced Diabetes mellitus in male albino rats. Biochem: an Indian J (BCAIJ) 2015;9(1):28-35.